DBV Technologies S.A. Cash Flow Conversion Efficiency

Latest as of March 2026: -0.236x

DBV Technologies S.A. cash flow conversion efficiency. Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.10 Million ≈ $-57.40 Million USD) by net assets (€207.90 Million ≈ $243.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DBV Technologies S.A. stock valuation for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of DBV Technologies S.A. (2011–2025)

Cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View DBV live share price for real-time trading data and today's change.

DBV Technologies S.A. Cash Flow Conversion Ratio Explained

DBV Technologies S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency. Review DBV Technologies S.A. financial flexibility index to assess the company's free cash flow relative to its total liabilities.

Company Cash Flow Conversion Efficiency
Suzhou Etron Technologies Co Ltd
SHG:603380
0.088x
TTY Biopharm Co Ltd
TWO:4105
0.088x
PPC Ltd
JSE:PPC
0.136x
Cromwell Property Group
AU:CMW
0.023x
Qian Jiang Water Resources Development Co Ltd
SHG:600283
0.031x
CHINA VANKE CO.LTD H YC 1
F:18V
N/A
Vats Liquor Chain Store Management Joint Stock Co Ltd
SHE:300755
0.146x
Relx PLC
LSE:REL
0.608x

Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2025)

The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. Also see DBV Technologies S.A. balance sheet assets for a full breakdown of the balance sheet.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €168.79 Million
≈ $197.33 Million
€-126.12 Million
≈ $-147.45 Million
-0.747x +80.41%
2024-12-31 €27.39 Million
≈ $32.02 Million
€-104.47 Million
≈ $-122.14 Million
-3.815x -571.38%
2023-12-31 €140.19 Million
≈ $163.89 Million
€-79.65 Million
≈ $-93.12 Million
-0.568x -98.41%
2022-12-31 €194.50 Million
≈ $227.39 Million
€-55.70 Million
≈ $-65.12 Million
-0.286x +73.74%
2021-12-31 €99.27 Million
≈ $116.06 Million
€-108.24 Million
≈ $-126.55 Million
-1.090x -65.92%
2020-12-31 €252.01 Million
≈ $294.62 Million
€-165.61 Million
≈ $-193.61 Million
-0.657x +12.28%
2019-12-31 €218.05 Million
≈ $254.92 Million
€-163.34 Million
≈ $-190.96 Million
-0.749x +33.50%
2018-12-31 €165.78 Million
≈ $193.81 Million
€-186.74 Million
≈ $-218.32 Million
-1.126x -28.02%
2017-12-31 €182.88 Million
≈ $213.81 Million
€-160.91 Million
≈ $-188.12 Million
-0.880x -258.89%
2016-12-31 €267.90 Million
≈ $313.21 Million
€-65.68 Million
≈ $-76.79 Million
-0.245x -195.04%
2015-12-31 €384.24 Million
≈ $449.21 Million
€-31.93 Million
≈ $-37.33 Million
-0.083x +53.34%
2014-12-31 €182.22 Million
≈ $213.04 Million
€-32.45 Million
≈ $-37.94 Million
-0.178x +45.72%
2013-12-31 €74.09 Million
≈ $86.61 Million
€-24.31 Million
≈ $-28.42 Million
-0.328x -23.20%
2012-12-31 €66.84 Million
≈ $78.15 Million
€-17.80 Million
≈ $-20.81 Million
-0.266x +49.14%
2011-12-31 €19.79 Million
≈ $23.13 Million
€-10.36 Million
≈ $-12.11 Million
-0.524x --

About DBV Technologies S.A.

PA:DBV France Biotechnology
Market Cap
$629.64 Million
€538.56 Million EUR
Market Cap Rank
#10808 Global
#169 in France
Share Price
€1.82
Change (1 day)
-4.51%
52-Week Range
€1.57 - €4.27
All Time High
€83.51
About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more